Biotech Archives - Page 143 of 795

2 minute read

Why Is Gene Therapy Focused Voyager Therapeutics Stock Soaring Today?

January 2, 10:50 AM

Voyager Therapeutics Inc (NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), to advance pot

NVS

3 minute read

NRx Pharmaceuticals To Present Keynote Address On Ketamine Efficacy And Risks At Upcoming Sachs Neuroscience Innovation Forum In San Francisco

By Benzinga Newsdesk

January 2, 9:45 AM

The benefits of ketamine are clear, but so are the risksKetamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more than 1,000 patientsNRx

NRXP

3 minute read

American Medical Association Grants Cardio Diagnostics Holdings, Inc.’s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, A Dedicated CPT PLA Reimbursement Code

By Benzinga Newsdesk

January 2, 9:41 AM

Obtaining a CPT PLA code marks a key milestone in securing reimbursement from federal and private payers for, and expanding access to the innovative PrecisionCHD test powered by AI and epigeneticsCardio Diagnostics

CDIO

3 minute read

Citius Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Trial Of Its Mino-Lok Therapeutic To Salvage Catheters; Topline Results Expected 2Q 2024

By Benzinga Newsdesk

January 2, 9:37 AM

Topline results expected 2Q 2024Study enrolled a total of 241 patients; 109 catheter failures observedFirst-and-only antibiotic lock solution in development to salvage catheters in patients with CRBSICRANFORD, N.J., Jan.

CTXR

3 minute read

Coherus Announces U.S. Launch Of LOQTORZI; Offers First And Only FDA-Approved Treatment For NPC In All Lines Of Therapy

By Benzinga Newsdesk

January 2, 9:31 AM

– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with

CHRS

2 minute read

Establishment Labs Announces First U.S. Commercial Procedure With Motiva Flora Tissue Expander

By Benzinga Newsdesk

January 2, 9:10 AM

Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that the Motiva

ESTA

2 minute read

Biora Therapeutics Progresses Research Collaboration For The BioJet Systemic Oral Delivery Platform; Met Key Performance Milestones As Part Of Its Research Collaboration With AstraZeneca

By Benzinga Newsdesk

January 2, 9:09 AM

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its BioJet™ Systemic Oral Delivery Platform has met key performance milestones as part of

AZN

3 minute read

Spero Therapeutics Announces First Patient, First Visit For Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr In Complicated Urinary Tract Infections; Spero Is Entitled To Receive $95M In Development Milestone Payments From GSK Over 2 Years

By Benzinga Newsdesk

January 2, 9:07 AM

Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and

SPRO

1 minute read

China Approves AstraZeneca-Sanofi’s Respiratory Syncytial Virus Drug To Prevent Infection In Infants

By Vandana Singh

January 2, 8:53 AM

Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASD

AZN

1 minute read

Verona Pharma’s Promising COPD Treatment Puts It in GSK’s Acquisition Crosshairs, Analysts Predict Big Moves

By Vandana Singh

December 29, 2:24 PM

In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion (£1.6 billion) range over the upcoming six months, aiming to fortify its pipeline.

GSK